| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acalabrutinib for relapsed chronic lymphocytic leukaemia
|
Burki, Talha Khan
|
|
2016
|
17 |
2 |
p. e48
|
article
|
| 2 |
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
|
Vale, Claire L
|
|
2016
|
17 |
2 |
p. 243-256
|
article
|
| 3 |
Afatinib and chemotherapy in non-small-cell lung cancer
|
Brower, Vicki
|
|
2016
|
17 |
2 |
p. e47
|
article
|
| 4 |
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
|
Shaw, Alice T
|
|
2016
|
17 |
2 |
p. 234-242
|
article
|
| 5 |
Alectinib in crizotinib-resistant, ALK-positive NSCLC
|
Jassem, Jacek
|
|
2016
|
17 |
2 |
p. 134-135
|
article
|
| 6 |
Australian government proposes diagnostic payment cuts
|
Kenyon, Georgina
|
|
2016
|
17 |
2 |
p. 145
|
article
|
| 7 |
Cancer research: in need of introspection
|
Jalali, Rakesh
|
|
2016
|
17 |
2 |
p. 140-141
|
article
|
| 8 |
Cancer screening after unprovoked venous thrombosis
|
Lecumberri, Ramón
|
|
2016
|
17 |
2 |
p. 128-129
|
article
|
| 9 |
Collages for cancer
|
Lobo, Patricia
|
|
2016
|
17 |
2 |
p. 149
|
article
|
| 10 |
Complete clinical response in rectal cancer: a turning tide
|
Perez, Rodrigo Oliva
|
|
2016
|
17 |
2 |
p. 125-126
|
article
|
| 11 |
Correction to Lancet Oncol 2016; 17: 109
|
|
|
2016
|
17 |
2 |
p. e46
|
article
|
| 12 |
Correction to Lancet Oncol 2016; 17: 248, 252
|
|
|
2016
|
17 |
2 |
p. e46
|
article
|
| 13 |
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
|
Shore, Neal D
|
|
2016
|
17 |
2 |
p. 153-163
|
article
|
| 14 |
Excision margins for melanomas: how wide is enough?
|
Moncrieff, Marc
|
|
2016
|
17 |
2 |
p. 127-128
|
article
|
| 15 |
Familial risk in patients with carcinoma of unknown primary
|
Baker, Holly
|
|
2016
|
17 |
2 |
p. e48
|
article
|
| 16 |
Happygram
|
Burki, Talha Khan
|
|
2016
|
17 |
2 |
p. 152
|
article
|
| 17 |
Health experts welcome 40% sin tax on tobacco in India
|
Sharma, Dinesh C
|
|
2016
|
17 |
2 |
p. e49
|
article
|
| 18 |
Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?
|
Rimner, Andreas
|
|
2016
|
17 |
2 |
p. e43-e44
|
article
|
| 19 |
Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power? – Authors' reply
|
Riesterer, Oliver
|
|
2016
|
17 |
2 |
p. e44-e45
|
article
|
| 20 |
Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial
|
Glover, Mark
|
|
2016
|
17 |
2 |
p. 224-233
|
article
|
| 21 |
Hyperbaric oxygen therapy for radiation-induced injury: evidence is needed
|
Creutzberg, Carien L
|
|
2016
|
17 |
2 |
p. 132-134
|
article
|
| 22 |
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
|
Chanan-Khan, Asher
|
|
2016
|
17 |
2 |
p. 200-211
|
article
|
| 23 |
Ibrutinib in chronic lymphocytic leukaemia: alone or in combination?
|
Robak, Tadeusz
|
|
2016
|
17 |
2 |
p. 129-131
|
article
|
| 24 |
Limited screening with versus without 18F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial
|
Robin, Philippe
|
|
2016
|
17 |
2 |
p. 193-199
|
article
|
| 25 |
Liquid cancer biopsy: the future of cancer detection?
|
The Lancet Oncology,
|
|
2016
|
17 |
2 |
p. 123
|
article
|
| 26 |
Low-dose morphine for moderate cancer pain
|
Baker, Holly
|
|
2016
|
17 |
2 |
p. e47
|
article
|
| 27 |
Menopausal hormone therapy reduces liver cancer risk
|
Bagcchi, Sanjeet
|
|
2016
|
17 |
2 |
p. e50
|
article
|
| 28 |
NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer
|
Elsada, Ahmed
|
|
2016
|
17 |
2 |
p. 143-144
|
article
|
| 29 |
Precision oncology: origins, optimism, and potential
|
Prasad, Vinay
|
|
2016
|
17 |
2 |
p. e81-e86
|
article
|
| 30 |
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial
|
Walker, Irwin
|
|
2016
|
17 |
2 |
p. 164-173
|
article
|
| 31 |
Prophylactic dexamethasone for radiation-induced bone-pain flare
|
Ishiwata, Tsukasa
|
|
2016
|
17 |
2 |
p. e39-e40
|
article
|
| 32 |
Prophylactic dexamethasone for radiation-induced bone-pain flare – Authors' reply
|
Chow, Edward
|
|
2016
|
17 |
2 |
p. e40-e41
|
article
|
| 33 |
Proton radiotherapy for primary liver cancers
|
Granovetter, Michael
|
|
2016
|
17 |
2 |
p. e49
|
article
|
| 34 |
Rabbit anti-thymocyte globulin to prevent GVHD
|
Rambaldi, Alessandro
|
|
2016
|
17 |
2 |
p. 124-125
|
article
|
| 35 |
Rare cancers: a sea of opportunity
|
Boyd, Niki
|
|
2016
|
17 |
2 |
p. e52-e61
|
article
|
| 36 |
Redefining “rare” in paediatric cancers
|
Pui, Ching-Hon
|
|
2016
|
17 |
2 |
p. 138-139
|
article
|
| 37 |
Reducing treatment-related mortality in childhood cancers
|
Gilbert, Judith A
|
|
2016
|
17 |
2 |
p. e51
|
article
|
| 38 |
Research methods to change clinical practice for patients with rare cancers
|
Billingham, Lucinda
|
|
2016
|
17 |
2 |
p. e70-e80
|
article
|
| 39 |
Second cancer risk for Hodgkin's lymphoma survivors
|
Baker, Holly
|
|
2016
|
17 |
2 |
p. e50
|
article
|
| 40 |
Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer
|
Katz, Matthew S
|
|
2016
|
17 |
2 |
p. e41-e42
|
article
|
| 41 |
Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer – Authors' reply
|
Chang, Joe Y
|
|
2016
|
17 |
2 |
p. e42-e43
|
article
|
| 42 |
S-1 with leucovorin and oxaliplatin for advanced gastric cancer
|
ter Veer, Emil
|
|
2016
|
17 |
2 |
p. e41
|
article
|
| 43 |
Synergy in traditional Chinese medicine
|
Xue, Tianhan
|
|
2016
|
17 |
2 |
p. e39
|
article
|
| 44 |
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
|
Quoix, Elisabeth
|
|
2016
|
17 |
2 |
p. 212-223
|
article
|
| 45 |
57th American Society of Hematology Annual Meeting
|
Smith, Lan-Lan
|
|
2016
|
17 |
2 |
p. 142
|
article
|
| 46 |
The Dream Lab
|
van Dorn, Aaron
|
|
2016
|
17 |
2 |
p. 150
|
article
|
| 47 |
The Lake
|
Harding, Emilia
|
|
2016
|
17 |
2 |
p. 151
|
article
|
| 48 |
The Mwanza Cancer Project
|
Amadori, Dino
|
|
2016
|
17 |
2 |
p. 146-148
|
article
|
| 49 |
The promise and challenges of rare cancer research
|
Komatsubara, Kimberly M
|
|
2016
|
17 |
2 |
p. 136-138
|
article
|
| 50 |
The value of research collaborations and consortia in rare cancers
|
Blay, Jean-Yves
|
|
2016
|
17 |
2 |
p. e62-e69
|
article
|
| 51 |
TIME for a successful cancer vaccine in NSCLC?
|
Butts, Charles A
|
|
2016
|
17 |
2 |
p. 131-132
|
article
|
| 52 |
Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis
|
Renehan, Andrew G
|
|
2016
|
17 |
2 |
p. 174-183
|
article
|
| 53 |
Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial
|
Hayes, Andrew J
|
|
2016
|
17 |
2 |
p. 184-192
|
article
|
Journal description